Glycoprotein expression by adenomatous polyps of the colon

Progress in Biomedical Optics and Imaging - Proceedings of SPIE

Volumn 6916, Issue , 2008, Pages

  Roney, Celeste A ^a   Jianwu, Xie ^a   Biying, Xu ^b   Jabour, Paul ^a   Griffiths, Gary ^b   Summers, Ronald M ^a  

^a Imaging Probe Development Center   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Colon cancer; Computed tomography; Drug targeting; Polymerized liposomes; UEA 1

Indexed keywords

COLON CANCER; COMPUTED TOMOGRAPHIC COLONOGRAPHY (CTC); DRUG TARGETING; GLYCOPROTEIN EXPRESSION; POLYMERIZED LIPOSOMES;

COMPUTERIZED TOMOGRAPHY; DRUG DOSAGE; GENE EXPRESSION; ONCOLOGY; PROTEINS; RATS;

COMPUTER AIDED DIAGNOSIS;

EID: 44349097359     PISSN: 16057422     EISSN: None     Source Type: Conference Proceeding    
DOI: 10.1117/12.769224     Document Type: Conference Paper

References (43)

1. de la Chapelle, A., Genetic predisposition to colorectal cancer. Nat Rev Cancer, 2004. 4(10): p. 769-80.
2. Potter, J.D., Colorectal cancer: molecules and populations. J Natl Cancer Inst, 1999. 91(11): p. 916-32.
3. Lamlum, H., et al, The type of somatic mutation at APC in familial adenomatous polyposis is determined by the site of the germline mutation: a new facet to Knudson's 'two-hit' hypothesis. Nat Med, 1999.5(9): p. 1071-5.
4. Goss, K.H. and J. Groden, Biology of the adenomatous polyposis coli tumor suppressor. J Clin Oncol, 2000. 18(9): p. 1967-79.
5. Kobaek-Larsen, M., et al., Review of colorectal cancer and its metastases in rodent models: comparative aspects with those in humans. Comp Med, 2000. 50(1): p. 16-26.
6. Lynch, H.T., et al., Familial cancer syndromes: a survey. Cancer, 1977.39(4 Suppl): p. 1867-81.
7. Aaltonen, L.A., et al., Clues to the pathogenesis of familial colorectal cancer. Science, 1993. 260(5109): p. 812-6.
8. Aaltonen, L.A., et al., Replication errors in benign and malignant tumors from hereditary nonpolyposis colorectal cancer patients. Cancer Res, 1994. 54(7): p. 1645-8.
9. Fearon, E.R. and B. Vogelstein, A genetic model for colorectal tumor igenesis. Cell, 1990.61(5): p. 759-67.
10. Osborn, N.K. and D. A. Ahlquist, Stool screening for colorectal cancer: molecular approaches. Gastroenterology, 2005.128(1): p. 192-206.
11. Ahlquist, D.A. and J.A. Gilbert, Stool markers for colorectal cancer screening: future considerations. Dig Dis, 1996. 14(3): p. 132-44.
12. Levin, B., et al., Emerging technologies in screening for colorectal cancer: CT colonography, immunochemical fecal occult blood tests, and stool screening using molecular markers. CA Cancer J Clin, 2003. 53(1): p. 44-55.
13. Ahlquist, D.A., et al., Patterns of occult bleeding in asymptomatic colorectal cancer. Cancer, 1989. 63(9): p. 1826-30.
14. Limburg, P.J., et al, Prospective evaluation of fecal calprotectin as a screening biomarker for colorectal neoplasia. Am J Gastroenterol, 2003.98(10): p. 2299-305.
15. Dubrow, R., C.S. Kim, and A.K. Eldred, Fecal lysozyme: an unreliable marker for colorectal cancer. Am J Gastroenterol, 1992. 87(5): p. 617-21.
16. Nakayama, T., et al., ELISA for occult faecal albumin. Lancet, 1987.1(8546): p. 1368-9.
17. O'Connor, S.D., et al., Oral contrast adherence to polyps on CT colonography. J Comput Assist Tomogr, 2006. 30(1): p. 51-7.
18. Hollingsworth, M.A. and B.J. Swanson, Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer, 2004. 4(1): p. 45-60.
19. Jass, J.R., et al, Ulex europaeus agglutinin-1 binding in hereditary bowel cancer. Pathology, 1993. 25(2): p. 114-9.
20. Ezpeleta, I., et al., Preparation of Ulex europaeus lectin-gliadin nanoparticle conjugates and their interaction with gastrointestinal mucus. Int J Pharm, 1999. 191(1): p. 25-32.
21. Boland, C.R., R.S. Bresalier, and J.A. Roberts, Assay of lectin binding sites in colon cancer-associated mucins: comparison of fluorescence microscopy with a quantitative chromatographic technique. J Histochem Cytochem, 1988. 36(10): p. 1329-34.
22. Kuroki, T., et al., Lectin staining of neoplastic and normal background colorectal mucosa in nonpolyposis and polyposis patients. Dis Colon Rectum, 1991.34(8): p. 679-84.
23. Yonezawa, S., et al., Glycoconjugate with Ulex europaeus agglutinin-I-binding sites in normal mucosa, adenoma, and carcinoma of the human large bowel. J Natl Cancer Inst, 1982. 69(4): p. 777-85.
24. Yonezawa, S., et al., Binding of Ulex europaeus agglutinin-I in polyposis coli: comparative study with solitary adenoma in the sigmoid colon and rectum. J Natl Cancer Inst, 1983. 71(1): p. 19-24.
25. Brockhausen, I., Glycodynamics of mucin biosynthesis in gastrointestinal tumor cells. Adv Exp Med Biol, 2003.535: p. 163-88.
26. Dahiya, R., et al., Mucin oligosaccharide biosynthesis in human colonic cancerous tissues and cell lines. Cancer, 1992. 70(6): p. 1467-76.
27. Kim, Y.S., R. Isaacs, and J.M. Perdomo, Alterations of membrane glycopeptides in human colonic adenocarcinoma. Proc Natl Acad Sci USA, 1974. 71(12): p. 4869-73.
28. Hakomori, S., Aberrant glycosylation in cancer cell membranes as focused on glycolipids: overview and perspectives. Cancer Res, 1985. 45(6): p. 2405-14.
29. Velcich, A., et al., Colorectal cancer in mice genetically deficient in the mucin Muc2. Science, 2002. 295(5560): p. 1726-9.
30. Otori, K., et al., Emergence of adenomatous aberrant crypt foci (ACF) from hyperplastic ACF with concomitant increase in cell proliferation. Cancer Res, 1995. 55(21): p. 4743-6.
31. Limburg, P.J., et al., Immunodiscrimination of colorectal neoplasia using MUC1 antibodies: discrepant findings in tissue versus stool. Dig Dis Sci, 2000. 45(3): p. 494-9.
32. Lotan, R. and A. Raz, Lectins in cancer cells. Ann N Y Acad Sci, 1988. 551: p. 385-96; discussion 396-8.
33. Barondes, S.H., Soluble lectins: a new class of extracellular proteins. Science, 1984. 223(4642): p. 1259-64.
34. Watanabe, M., et al., Appearance of Ulex europaeus agglutinin-1 and Griffonia simplicifolia agglutinin-1 binding sites on cancer cells in sigmo-rectalpolyps. Acta Pathol Jpn, 1992. 42(11): p. 800-6.
35. Ouyang, D.L., et al., Noninvasive testing for colorectal cancer: a review. Am J Gastroenterol, 2005. 100(6): p. 1393-403.
36. Atkin, W. and J.P. Martin, Stool DNA-based colorectal cancer detection: finding the needle in the haystack. J Natl Cancer Inst, 2001. 93(11): p. 798-9.
37. Shamsuddin, A.M., A simple mucus test for cancer screening. Anticancer Res, 1996. 16(4B): p. 2193-9.
38. Hoskins, L.C. and E.T. Boulding, Mucin degradation in human colon ecosystems. Evidence for the existence and role of bacterial subpopulations producing glycosidases as extracellular enzymes. J Clin Invest, 1981. 67(1): p. 163-72.
39. Loktionov, A., et al., Quantitation of DNA from exfoliated colonocytes isolated from human stool surface as a novel noninvasive screening test for colorectal cancer. Clin Cancer Res, 1998.4(2): p. 337-42.
40. Ahlquist, D.A., et al., Morphometric analysis of the "mucocellular layer" overlying colorectal cancer and normal mucosa: relevance to exfoliation and stool screening. Hum Pathol, 2000.31(1): p. 51-7.
41. Ahlquist, D.A., et al., Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology, 2000. 119(5): p. 1219-27.
42. Boynton, K.A., et al., DNA integrity as a potential marker for stool-based detection of colorectal cancer. Clin Chem, 2003. 49(7): p. 1058-65.
43. Dong, S.M., et al., Detecting colorectal cancer in stool with the use of multiple genetic targets. J Natl Cancer Inst, 2001. 93(11): p. 858-65.